Heron Therapeutics is trading at $0.37, up 7.34%, amid broader rate sentiment after weak September payrolls eased rate-hike concerns and supported equities.
- Earlier after-hours coverage linked Heron Therapeutics’ gain to the macro backdrop, not a new company announcement today.
- No fresh company-specific catalyst was found for October 5.
- The Long Grove multi-product license agreement was announced September 29, not today.